Stock markets and equity markets have natural life cycles. As biotech stocks have risen over the past year, an increasing number of companies have raised significant sums through equity offerings. Yet these companies have substantial funding needs because they're moving into later-stage development.

That combination of a rising market and later-stage companies with significant funding requirements has created growing interest on the part of both investors and companies in a variety of debt instruments, particularly convertible debentures.